Drugs acting on imidazoline receptors. A review of their pharmacology, their use in blood pressure control and their potential interest in cardioprotection

Drugs

Volumn 58, Issue 5, 1999, Pages 799-812

  Bousquet, Pascal ^a   Feldman, Josiane ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

6 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 1H 3 BENZAZEPINE; ALPHA 2 ADRENERGIC RECEPTOR; ANTIHYPERTENSIVE AGENT; ATENOLOL; CLONIDINE; ENALAPRIL; HYDROCHLOROTHIAZIDE; IMIDAZOLINE RECEPTOR; METHYLDOPA; MOXONIDINE; NIFEDIPINE; RILMENIDINE;

AFFECTIVE NEUROSIS; AUTONOMIC NERVOUS SYSTEM; BLOOD PRESSURE REGULATION; BRADYCARDIA; CLINICAL TRIAL; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG TOLERABILITY; HEART ARRHYTHMIA; HEART LEFT VENTRICLE HYPERTROPHY; HEART OUTPUT; HEART PROTECTION; HEART RATE; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPONATREMIA; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; NONHUMAN; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; PARASYMPATHETIC NERVE; RECEPTOR AFFINITY; REVIEW; SEXUAL DYSFUNCTION; SLEEP DISORDER; SOMNOLENCE; SYMPATHETIC NERVE; VERTIGO; XEROSTOMIA;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ARRHYTHMIA; CLINICAL TRIALS; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; IMIDAZOLES; OXAZOLES; RECEPTORS, DRUG;

EID: 0032761333     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199958050-00003     Document Type: Review

References (110)

1. 2-Receptor Stimulations. Steinkopf Verlag Darmstadt 1993: 257-64
2. Reid JL, Wing LMH, Dargie HJ, et al. Clonidine withdrawal in hypertension: Changes in blood pressure and plasma and urinary noradrenaline. Lancet 1977; 1: 1171-4
3. Bousquet P. Recent advances in imidazoline receptor research. Exp Opin Invest Drugs 1995; 4 (5): 431-42
4. Molderings GJ. Imidazoline receptors: Basic knowledge, recent advances and future prospects for therapy and diagnosis. Drugs Future 1997; 22 (7): 757-72
5. Chan CKS, Head C.A. Relative importance of central imidazoline receptors for the antihypertensive effects of moxonidine and rilmenidine. J Hypertens 1996; 14: 855-64
6. 1-imidazoline receptor: From binding site to therapeutic target in cardiovascular disease. J Hypertens 1997; 15 Suppl. 1: S9-S23
7. Scriabine A, Methyldopa. In: Scriabine A, editor. Pharmacology of Antihypertensive Drugs. New York (NY): Raven Press, 1980: 43-54
8. Bousquet P, Feldman J, Schwartz J. Central cardiovascular effects of alpha-adrenergic drugs: Differences between catecholamines and imidazolines. J Pharmacol Exp Ther 1984; 230: 232-6
9. Bousquet P, Feldman J, Bloch R, et al. The nucleus reticularis lateralis, a region highly sensitive to clonidine. Eur J Pharmacol 1981; 69: 389-92
10. 1-imidazoline binding site is a functional receptor mediating vasodepression via the ventral medulla. Am J Physiol 1997; 273 (5 Pt 2): R1572-9
11. Tibirica E, Feldman J, Bousquet P. Difference in the ability of yohimbine to antagonize the hypotensive effect of clonidine in normotensive and spontaneously hypertensive anaesthetized rats. J Pharmacol Exp Ther 1988; 244: 1062-6
12. Chan CKS, Sannajust F, Head GA. Role of imidazoline receptors in the cardiovascular actions of moxonidine, rilmenidine and clonidine in conscious rabbits. J Pharmacol Exp Ther 1996, 276: 411-20
13. Guyenet PG. Do imidazoline binding sites play a role in the efficacy of clonidine and related centrally acting sympatholytic drugs? Am J Physiol 1997; 42: R1580-4
14. 2-adrenoceptors. Br J Pharmacol 1993; 110: 1635-9
15. 2-adrenoceptors in the cardiovascular effects of moxonidine. Eur J Pharmacol 1995; 282: 19-28
16. 2A-adrenergic subtype. Science 1996; 273: 801-3
17. Sannajust P, Head GA. Rilmenidine-induced hypotension in conscious rabbits involves imidazoline-preferring receptors. J Cardiovasc Pharmacol 1994; 23: 42-50
18. Head GA, Burke SL, Chan CKS. Site and receptors involved in the sympathoinhibitory actions of rilmenidine. J Hypertens 1998; 16 Suppl. 3: S7-S12
19. 2-adrenoceptors in the central hypotensive effects of imidazoline like-drugs. Ann N Y Acad Sci 1999 Jun 21; 881: 272-8
20. Tihirica E, Mermet C, Feldman J, et al. Correlation between the inhibitory effect on catecholaminergic ventrolateral medullary neurons and the hypotension evoked by clonidine: A voltammetric approach. J Pharmacol Exp Ther 1989; 250: 642-7
21. Tibirica E, Feldman J, Mermet C, et al. Selectivity of rilmenidine for the nucleus reticularis lateralis, a ventrolateral medullary structure containing imidazoline preferring receptors. Eur. J Pharmacol 1991; 209: 213-21
22. 2-adrenoreceptors affect sleep and arousal mechanisms. Br J Pharmacol 1987; 90: 675-85
23. Reis DJ, Bousquet P, Parini A. The imidazoline receptors: Pharmacology, functions, ligands, and relevance to biology and medicine. Ann N Y Acad Sci 1995; 763: 1-707
24. Heemskerk FJM, Dontenwill M, Grency H, et al. Evidence for the existence of imidazoline specific binding sites in synaptosomal plasma membranes of the bovine brainstem. J Neurochem 1998; 171: 2193-202
25. +. J Pharmacol Exp Ther 1995; 276: 359-64
26. Raddatz R, Parini A, Lanier SM. Localization of the imidazoline binding domain on monoamine oxidase B. Mol Pharmacol 1997; 52: 549-53
27. 2-adrenoceptors. Ann N Y Acad Sci 1999 Jun 21; 881: 123-34
28. Ivanov TR, Cay Jones J, Dontenwill M, et al. Characterization of a partial cDNA clone detected by imidazoline receptorselective antisera. J Auton Nerv Syst 1998; 72: 98-110
29. Li G, Regunathan S, Barrow CJ, et al. Agmatine: An endogenous clonidine displacing substance in the brain. Science 1994; 263: 966-9
30. Atlas D, Burstein Y. Isolation and partial purification of a clonidine displacing endogenous brain substance. Eur J Biochem 1984; 144; 287-93
31. Regunathan S, Reis DJ. Imidazoline receptors and their endogenous ligands. Annu Rev Pharmacol Toxicol 1996; 36: 511-44
32. Felsen D, Ernsberger P, Sutaria PM, et al. Identification, localization and functional analysis of imidazoline and alpha-adrenergic receptors in canine prostate. J Pharm Exp Ther 1994; 268: 1063-71
33. 2-adrenoceptor subtypes. J Pharmacol Exp Ther 1996; 279: 694-702
34. 1-imidazoline receptors: Definition, characterization, distribution and transmembrane signalling. Ann N Y Acad Sci 1995; 763; 22-42
35. 1-imidazoline receptors mediate arachidonic acid release from PC12 pheochromocytoma cells [abstract]. FASEB 1995; 9: A114
36. 1-imidazoline receptors in PC12 cells and rostral ventrolateral medulla. Brain Res 1997; 749: 335-49
37. Regunathan S, Evinger MJ, Meeley MP, et al. Effects of clonidine and other imidazole-receptor binding agents on second messenger systems and calcium influx in bovine adrenal chromalfin cells. Biochem Pharmacol 1991; 42: 2011-8
38. Ernsberger P, Giuliano R, Willette RN, et al. Role of imidazole receptors in the vasodepressor response to clonidine analogs in the rostro-ventrolateral medulla. J Pharmacol Exp Ther 1990; 253: 408-18
39. Bouquet P. Imidazoline receptors. Neurochem Int 1997; 30: 3-7
40. Bricca G, Dontenwill M, Molines A, et al. Rilmenidine selectivity for imidazoline receptors in human brain. Eur J Pharmacol 1989; 163: 373-7
41. Ernsberger P, Elliott HL, Weimann HJ, et al. Moxonidine: A second generation central hypertensive agent. Cardiovasc Drugs Rev 1993; 11: 411-31
42. Verbcuren TJ, Dinh Xuan AT, Koenig-Bérard E, et al. Rilmenidine. Cardiovasc Drug Rev 1990; 8: 56-70
43. 1 receptor agonist moxonidine. Eur J Clin Res 1995; 7: 227-40
44. Feldman J, Tibiriça E, Bricca G, et al. Evidence for the involvement of imidazoline receptors in the central hypotensive effect of rilmenidine in the rabbit. Br J Pharmacol 1990; 100: 600-4
45. 1-imidazoline agonist moxonidine administered inlo the rostral ventrolateral medulla. J Cardiovasc Pharmacol 1992; 20 Suppl. 4: S11-S15
46. Harron DWG. Antihypertensive drugs and baroreflex sensitivity effect of rilmenidine. Am J Med 1989; 87 Suppl. 3C: 57S-62S
47. Roegel JC, Yannoulis N, De Jong W, et al. Inhibition of centrally induced ventricular arrhythmias by rilmenidine and idazoxan in rabbits. Naunyn Schmiedeberg's Arch Pharmacol 1996; 354: 598-605
48. Mammoto T, Kamabuyashi T, Hayashi T, et al. Antiarrhythmic of rilmenidine on adrenaline-induced arrhythmia via central imidazoline receptors in halothane anaesthetized dogs. Br J Pharmacol 1996; 117: 1744-8
49. Roegel JC, Yannoulis N, De Jong W, et al. Preventive effect of rilmedine on the occurrence of neurogenic ventricular arrhythmias in rabbits. J Hypertens 1998: 16 Suppl. 3: S39-S43
50. Lepran I, Papp J.P. Effect of moxonidine on arrhythmias induced by coronary artery occlusion and reperfusion. J Cardiovasc Pharmacol 1994; 24 Suppl. 1: S9-S15
51. + transport and intracellular pH in renal proximal tubule cells. Biochim Biophys Acta 1990; 1024: 173-8
52. + exchange in proximal tubule cells and cortical collecting duct Kidney Int 1997; 52: 454-9
53. Mayorov D, Chernobelski M, Medvedev O. Sympathoinhibitory action of rilmenidine in concious sinoaortically denervated rats. J Cardiovasc Pharmacol 1993; 22: 314-20
54. Kline RL, Cechetto DF. Renal effects of rilmenidine in anesthetized rats: Importance of renal nerves. J Pharmacol Exp Ther 1993; 266: 1556-62
55. Ghaemmaghami F, Ibanez J, Geclen G, et al. Effects of swim training alone and combination with clonidine and rilmenidine on blood pressure, plasma electrolytes, vasopressine, and renin activity in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1990; 15: 68-74
56. Dollery CT, Davies DS, Duchier J, et al. Dose and concentration-effect relations for rilmenidine. Am J Cardiol 1988; 61: 60D-66D
57. Ostermann G, Brisgand B, Schmitt J, et al. Efficacy and accept ability of rilmenidine. Am J Cardiol 1988; 61: 76D-80D
58. Fillastre JP, Letac B, Galinier F, et al. A multicenter doubleblind comparative study of rilmenidine and clonidine in 333 hypertensive patients. Am J Cardiol 1988; 61: 81D-5D
59. Galley P, Manciet G, Hessel JL, et al. Antihypertensive efficacy and acceptability of rilmenidine in elderly hypertensive patients. Am J Cardiol 1988; 61: 86D-90D
60. De Divitiis O, Di Somma S, Liguori V, et al. Effort blood pressure control in the course of antihypertensive treatment. Am J Med 1989; 87 (3C): 46S-56S
61. Fiorentini C, Guillet C, Guazzi M. Elude multicentrique en double aveugle comparant la rilmenidine 1 mg et l'hydrochlorothiazide 25mg chez 244 patients. Arch Mal Cocur 1989; 82: 39-46
62. Seemama M, Fevrier B, Beucler I, et al. Lipid profile and antihypertensive efficacy in dyslipidemic hypertensive patients: Comparison of rilmenidine with captopril. Imidazoline receptors in a comprehensive approach to hypertension. J Cardiovasc Pharmacol 1995; 26 Suppl. 2: 534-9
63. Panfilov V, Morris AD, Donnely R, et al. Comparative effects of rilmenidine and atenolol on tests of autonomic function and mental and dynamic exercise in patients with essential hypertension. J Cardiovasc Pharmacol 1995; 26 Suppl. 2: S44-7
64. Germano G, Guillet C. Effects de la rilmenidine sur I'équilibre hydro-électrolytique. JAMA 1990; Suppl.: 45-50
65. Cechetto DF, Kline RI. Complementary antihypertensive action of rilmenidine on the pressure-natriuresis relationship and sodium preference in spontaneously hypertensive rats. J Hypertens 1998; 16 Suppl. 3: S7-S12
66. Trimarco B, Morisco C, Sarno D, et al. Rilmenidine in patients with left ventricular hypertrophy: Beyond the reduction of left ventricular mass. J Cardiovasc Pharmacol 1995; 26 Suppl. 2: S29-S33
67. Sadowski Z, Szwed H, Kuch-Wocial A, et al. Regression of left ventricular hypertrophy in hypertensive patients after a one, year treatment with rilmenidine: A double blind, randomised, controlled (versus nifedipine) study. J Hypertens 1998; 16 Suppl. 3: S55-S62
68. Beau B, Mahieux F, Paraire M, et al. Efficacy and safety of rilmenidine for arterial hypertension. Am J Cardiol 1988; 61: 95D-102D
69. Laubie M, Poignant JC, Seuvee-Moreau J, et al. Pharmacological properties of (N-dicyclopropyl-methylamino-2-oxazoline (S3341), an α_adrenoceptor agonist. J Pharmacol (Paris) 1985; 16: 259-78
70. Van Zwieten PA, Thoolen MHMC, Jonkman FAM, et al. Central and peripheral effects of S 3341 I(N-dicyclopropylmethyl)amino-2-oxazolinel in animal models. Arch Int Pharmacodyn Ther 1986; 279(1): 130-49
71. Mahieux F, Rilmenidine and vigilance: Review of clinical studics. Am J Med 1989; 87(3C): 67S-72S
72. Pillion G, Fevrier B, Codis P, et al. Long term control of blood pressure in high risk population. 6th European Meeting on Hypertension; 1993 Jun 13, Milan
73. Lins RL, Daclemans R, Dratwa M, et al. Acceptability of rilmenidine and long-term surveillance of plasma concentration in hypertensive patients with renal insufficiency. Am J Med 1989; 87 (3C): 41S-45S
74. Jahn H. Etude de l'Activité Antihypertensive et de l'Acceptabilité d'Hyperium 1 mg Chez l'Hypertendu Insuffisant Rénal. Paris: Laboratoires Biopharma. Hypérium clinical evaluation program. 1986 Jul. (Data on file)
75. Aparicio M, Dratwa M, Fillastre JP, et al. Pharmacokinetics of rilmenidine in patients with chronic renal insufficiency and in hemodialysis patients. 6th European Meeting on Hypertension; 1993 Jun 13, Milan
76. Lubetzki J. Etude de l'Activité Antihypertensive et de l'Acceptabilité, d'Hyperium chez l'Hypertendu Diabétique non Insulino-dépendant. Paris: Laboratoires Biopharma, Hypérium clinical evaluation program, 1986 Jul. (Data on file)
77. Mpoy M, Van de Leene B, Ketelslegers JM, et al. Treatment of systemic hypertension in insulin-treated diabetic mellitus with rilmenidine. Am J Card 1988; 61: 91D-94D
78. 1-imidazoline sites. J Pharmacol Exp Ther 1993; 264: 172-82
79. 1imidazoline Receptor Agonist Moxonidine: A New Antihypertensive. London: Royal Society of Medicine, 1996: 43-77
80. Küppers HE, Jäger BA, Luszick JH, et al. Placebo-controlled comparison of the efficacy and tolerability of once daily moxonidine and enalapril in mild to moderate essential hypertension. J Hypertens 1997; 15: 93-7
81. Kraft K, Vetter H. 24-hour blood pressure profiles in patients with mild-to-moderate hypertension: Moxonidine versus captopril. J Cardiovasc Pharmacol 1994; 24 Suppl. 1: S29-S35
82. Lotti G, Gianrossi R. Moxonidine vs. Captopril bei leicher bis mittelllshwerer Hypertonic. Doppelblindstudie zur Wirksamkeit und Verträglichkeit. Fortshr Med 1993; 111: 429-32
83. Plänitz V. Crossover comparison of moxonidin and clonidine in mild to moderate hypertension. Eur J Clin Pharmacol 1984; 27: 147-52
84. Wolf R. The treatment of hypertensive patients with a calcium antagonist or moxonidine: A comparison. J Cardiovasc Pharmacol 1992; 20 Suppl. 4: S42-S44
85. Prichard BNC, Simmons R, Rooks J, et al. A double-blind comparison of moxonidine and atenolol in the management of patients with mild to moderate hypertension. J Cardiovasc Pharmacol 1992; 20 Suppl. 4: S45-S49
86. Frei M, Kuster L, Gordosch von Krosigk PP, et al. Moxonidine and hydrochlorothiazide in combination: A synergistic antihypertensive effect. J Cardiovasc Pharmacol 1994; 24 Suppl. 1: 25-8
87. Schwartz VW, Kandziora J. Langzeiterfahrungen mit moxonidin, einem neuen antihypertensivum. Fortschr Med 1990; 108 (32): 64-70
88. Mitrovic V, Strasser R, Walenta R, et al. Haemodynamic and neurohumoral effects of a single oral dose of the imidazoline II agonist moxonidine in patients with dilated cardiomyopathy and heart failure. Eur J Clin Res 1996; 8: 149-61
89. Swedberg K. Effects of moxonidine in hemodynamics and sympathetic activation in congestive heart failure [abstract] XIX Congress of the European Society of Cardiology: 1997 Aug 24-28; Stockholm
90. Wilkens H, Wilkens HJ, Fabel H. Die Wirkung von Moxonidin-einem zentral wirksamen antihypertensivum-aul atemregulation und histaminreaktivität. Kardio 1992; 10(11): 1-4
91. Eichstaed H, Schroeder RJ, Auffermann W, et al. Regression of left ventricular hypertrophy. J Cardiovasc Pharmacol 1992; Suppl. 1: S55-S61
92. Eichstaed H, Richter W, Bäder M, et al. Demonstration of hypertrophy regression with magnetic resonance tomography under the new adrenergic inhibitor moxonidine. Cardiovasc Drugs Ther 1989; 3 Suppl. 2: 583-7
93. Hüting J, Mitrovic V, Bahavar H, et al. Vergleich der wirkungen von moxonidin and nifedipine auf die links ventriculäre funktion bei monotherapie der essentiellen hypertonie. Herz Kreislauf 1992; 24: 132-6
94. Eichstaed H, Gatz G, Schröder R, et al. Linksventrikuläre hypertrophieregression unter einer therapie mit moxonidin. Pharmacol Ther 1991; 1: 12-7
95. Motz W, Vogl M, Scheler S, et al. Hypertensive coronary microcirculation-effects of the imidazoline-receptor agonist moxonidine. Cardiovasc Risk Factors 1995; 5 Suppl. 1: 28-32
96. Wieseck A, Fliser D, Nowicki M, et al. Effect of moxonidine on urinary electrolyte excretion and renal haemodynamic in man. Eur J Clin Pharmacol 1995; 48: 203-8
97. 2-agonists have slighter CNS side effects than postsynaptic agonists? A comparison of moxonidine and clonidine. Eur J Clin 1989; 36 Suppl.: A45-A48
98. MacPhec GJA, Howie CA, Elliott HL, et al. A comparison of haemodynamic and behavioural effects of moxonidine and clonidine in normotensive subjects. Br J Clin Pharmacol 1992; 33: 261-7
99. Barron H, Lesh MD. Autonomic nervous system and sudden cardiac death. J Am Coll Cardiol 1996; 27 (5): 1053-60
100. Roegel JC, Yannoulis N, De Jong W, et al. Preventive effect of rilmenidine on the occurence of neurogenic ventricular arrythmias in rabbits. J Hypertens 1998; 16 Suppl. 3: S39-S43
101. Lepran J, Papp JG. Effect of moxinidine on arrythmias induced by coronary artery occlusion and reperfusion. J Cardiovasc Pharmacol 1994; 24 Suppl, 1: S9-S15
102. McKaigue JP, Harron DWG. The effects of rilmenidine on tests of autonomic function in humans. Clin Pharmacol Ther 1992; 52:511-7
103. White CM. Catecholamines and their blockade in congestive heart failure. Am J Health Syst Pharm 1998; 55 (7): 676-82
104. Zhang YH, Zhu J, Song YC. Suppressing sympathetic activation with clonidine on ventricular arrhythmias in congestive heart Failure. Int J Cardiol 1998; 65 (3): 233-8
105. Zhang YH, Song YC, Zhu J, et al. Sympathetic inhibition with clonidine improves autonomic balance in congestive heart failure. Int J Cardiol 1997; 59: 139-44
106. Azevedo ER, Newton GE, Parker JD. Cardiac sympathetic activity in response to clonidine in human heart failure. Circulation 1997; 96 Suppl. 8: 1-94
107. Manolis AJ, Olympios C, Sifaki M, et al. Chronic sympathetic suppression in the treatment of chronic congestive heart failure. Clin Exp Hypertens 1998; 20 (7): 717-31
108. Manolis AJ, Olympios C, Sifaki M, et al. Suppressing sympathetic activation in congestive heart failure. Hypertension 1995; 26: 719-24
109. Plänitz V. Long-term experience with moxonidine in arterial hypertension [abstract]. Acta Pharmacol Toxicol 1986; 59 Suppl. 5: 277
110. Koenig-Berard E, Tierney C, Beau B, et al. Cardiovascular and central nervous system effects of rilmenidine (S3341) in rats. Am J Cardiol 1988; 61: 22D-31D